Menopause: What Actually Happens to Your Body and Why It Matters for Longevity

Menopause is often reduced to hot flashes, night sweats and the end of menstrual periods. Those are real parts of the transition, but they are not the whole story.

The years surrounding menopause are a period of substantial physiologic change. Ovarian estrogen production becomes increasingly erratic during perimenopause and then falls after the final menstrual period. Ovulation becomes less frequent, progesterone exposure changes, and eventually reproductive cycling stops.

Some women move through this transition with relatively few symptoms. Others experience years of disrupted sleep, vasomotor symptoms, vaginal and urinary changes, altered body composition, mood changes, joint complaints, changes in sexual function, or difficulty concentrating.

At the same time, women are getting older. Blood pressure may be rising. Lean mass may be falling. Visceral fat can increase. Cardiovascular risk factors become more important. Bone loss accelerates around the final menstrual period.

Good menopause care requires separating what is likely related to ovarian aging from what may be coming from sleep, thyroid disease, iron deficiency, metabolic dysfunction, medication effects, depression, cardiovascular disease, or simply the biology of aging itself.

Menopause Is a Point in Time. Perimenopause Is the Transition.

Menopause itself has a specific definition: 12 consecutive months without menstrual bleeding. The transition leading to that point is perimenopause, and it can last for several years.

During perimenopause, hormone production is not simply declining in a smooth line. Estrogen can fluctuate substantially. Ovulation becomes less predictable. Menstrual cycles may shorten, lengthen, become heavier or lighter, or disappear for months and then return.

This variability is one reason a single estrogen measurement is often less informative than people expect. In a woman in the typical age range with characteristic menstrual changes and symptoms, the diagnosis of the menopausal transition is usually clinical rather than dependent on repeatedly measuring reproductive hormones.

Laboratory testing still has an important role when the history is atypical or when another medical condition needs to be excluded. Thyroid disease, anemia, iron deficiency, pregnancy, medication effects and other endocrine disorders can produce symptoms that overlap with menopause.

Hot Flashes Are Only One Part of the Story

Vasomotor symptoms include hot flashes and night sweats. For some women they are occasional and mildly inconvenient. For others they occur repeatedly throughout the day and night and interfere with sleep, work, exercise and concentration.

Night sweats can fragment sleep even when a woman does not fully remember waking. Sleep disturbance can then amplify fatigue, appetite changes, irritability, pain sensitivity and difficulty concentrating the following day.

Not every sleep problem in midlife should be blamed on estrogen. Insomnia, obstructive sleep apnea, restless legs, alcohol, medications, anxiety and other medical conditions remain part of the differential diagnosis.

Sleep Environment, Depth, Mental Health, and Longevity

Weight Gain Is More Complicated Than “Menopause Slowed My Metabolism”

Many women notice that their body changes in midlife even when the scale has not changed dramatically. The waist becomes larger. Fat that was once stored primarily under the skin becomes more concentrated around the abdomen. Maintaining muscle becomes more difficult without deliberate resistance training and adequate protein.

Menopause is part of that story, but it is not the only part.

Longitudinal research suggests that aging itself accounts for much of the increase in total body weight seen during midlife. The menopausal transition appears to contribute more specifically to changes in body composition and fat distribution, including greater central and visceral adiposity.

Sleep disruption, declining physical activity, inadequate resistance training, medication effects, insulin resistance, alcohol intake and dietary changes can compound the problem.

Calling all midlife weight gain a hormone problem is too simple. Calling it merely a failure of discipline is worse.

Body composition is often more informative than body weight alone because two women at the same weight can have very different amounts of visceral fat and lean tissue.

• Insulin Resistance Explained
• Triglycerides and Longevity

Bone Loss Accelerates Around Menopause

Bone is living tissue. Throughout adulthood, old bone is continuously removed and new bone is formed. With aging, that balance gradually shifts toward greater bone loss.

The decline in estrogen around menopause accelerates that process. Bone loss becomes particularly rapid around the final menstrual period and in the first several years afterward.

This is one of the clearest reasons to think beyond symptom relief. A woman can feel perfectly well while losing bone.

Bone health should be considered in the context of age, family history, previous fractures, body weight, smoking, alcohol, medications, vitamin D and calcium intake, resistance exercise, balance, muscle strength and other medical conditions. DEXA testing is appropriate when screening criteria or individual risk support it.

Menopausal hormone therapy also reduces bone loss and fracture risk while it is being used, although the decision to use systemic hormone therapy should be based on the woman's complete clinical picture rather than bone density alone.

The Cardiovascular Conversation Changes in Midlife

Cardiovascular disease remains the leading cause of death among women, and cardiovascular risk rises with age. Menopause occurs during the same period when blood pressure, cholesterol, insulin resistance and visceral adiposity often become more clinically important.

Estrogen affects vascular biology and lipid metabolism, but it would be misleading to say that menopause by itself suddenly causes cardiovascular disease. Age, genetics, blood pressure, apoB-containing lipoproteins, diabetes, smoking, physical activity, body composition and other risk factors remain central.

Menopause is therefore a useful time to stop thinking only about symptoms and reassess cardiovascular prevention.

That may include blood pressure, lipid and apoB assessment, Lp(a) when appropriate, glucose metabolism, smoking status, family history, exercise and body composition. Imaging can be useful in selected patients when the result will meaningfully change risk assessment or treatment.

Preventive Cardiology and Longevity Medicine

Brain Fog Is Real, but It Does Not Mean the Brain Is Failing

Many women describe changes in attention, word retrieval, working memory or mental efficiency during the menopausal transition. Sleep disruption, vasomotor symptoms, mood symptoms and hormonal changes may all contribute.

These complaints deserve to be taken seriously without turning every lapse in memory into evidence of neurodegenerative disease.

Persistent or progressive cognitive symptoms still require an appropriate medical evaluation. Thyroid disease, sleep apnea, depression, medications, alcohol use, nutritional deficiencies and neurologic disease should not disappear from consideration simply because a woman is in perimenopause.

Menopausal hormone therapy should not be prescribed simply to prevent dementia. Its principal indications remain treatment of appropriate menopausal symptoms and, in selected women, prevention of bone loss.

Mood Can Change During the Menopausal Transition

Some women experience greater irritability, anxiety or vulnerability to depression during perimenopause. Sleep loss and vasomotor symptoms can intensify those problems. Women with a previous history of mood disorders may be particularly vulnerable during periods of hormonal change.

It is important not to reduce this to “just hormones.” Depression and anxiety remain real clinical disorders and deserve appropriate treatment when present. Menopause may be part of the context rather than the entire explanation.

Vaginal and Urinary Symptoms Are Common and Often Under-Treated

Declining estrogen changes vaginal, vulvar and lower urinary-tract tissues. The vaginal lining can become thinner, drier and less elastic. Some women develop burning, irritation, painful intercourse, urinary urgency or recurrent urinary tract symptoms.

These changes are now grouped under the term genitourinary syndrome of menopause, or GSM.

Unlike hot flashes, which often improve with time, GSM commonly persists or progresses without treatment.

Vaginal moisturizers and lubricants may be enough for mild symptoms. Low-dose vaginal estrogen and other prescription therapies are effective options for many women when symptoms are more significant. Treatment should be individualized, particularly in women with a history of estrogen-sensitive cancer.

Hair Changes May Be Hormonal, but Hair Loss Still Needs a Differential Diagnosis

Hair diameter and cycling can change during and after menopause. Some women notice a widening central part, reduced crown density or more diffuse shedding.

Menopause does not automatically explain the problem. Female-pattern hair loss, thyroid disease, rapid weight loss, inadequate protein or calorie intake, iron deficiency, medications, telogen effluvium, autoimmune alopecia and inflammatory scalp disease can all produce hair loss in midlife.

If your hair density or shedding has changed, the HormoneSynergy® Hair Loss Assessment can help organize the pattern, timing, hormone changes, thyroid clues, nutrition, weight change and other factors that may deserve further evaluation.

Menopausal Hormone Therapy: What It Does Well

Menopausal hormone therapy has accumulated decades of research, misunderstanding, abrupt swings in public opinion and, more recently, a more individualized interpretation of benefit and risk.

Systemic estrogen remains the most effective treatment for bothersome hot flashes and night sweats. It also treats many menopause-related sleep complaints when vasomotor symptoms are driving the sleep disruption and helps prevent the accelerated bone loss associated with menopause.

A woman who still has a uterus generally requires adequate progestogen along with systemic estrogen to protect the endometrium from estrogen-induced hyperplasia and cancer.

For many healthy women with significant symptoms who begin treatment before age 60 or within approximately 10 years of menopause, major menopause societies consider the benefit-risk balance favorable when there are no contraindications.

That does not mean hormone therapy is appropriate for everyone.

Age, time since menopause, personal and family history, unexplained vaginal bleeding, thrombotic history, cardiovascular disease, stroke risk, liver disease, breast cancer history and other factors may change the decision considerably.

Route and Formulation Can Matter

Hormone therapy is not one drug or one route of administration.

Estrogen may be administered orally or through the skin with a patch, gel or spray. Vaginal estrogen can be used locally for genitourinary symptoms. Progesterone or another progestogen is added when endometrial protection is required.

Oral estrogen undergoes first-pass metabolism through the liver and has different effects on coagulation proteins and triglycerides than transdermal estrogen. Observational evidence suggests that transdermal estrogen may carry a lower risk of venous thromboembolism than oral therapy in appropriate women, although individual risk still requires consideration.

The choice should be driven by the woman in front of us, not by loyalty to one product, dose or delivery system.

Hormone Therapy Is Not a Longevity Drug

Menopause occurs at an important point in a woman's health trajectory, which makes hormone therapy an easy subject for longevity marketing.

That can get ahead of the evidence.

Hormone therapy can substantially improve quality of life for appropriately selected symptomatic women and can prevent bone loss while it is being used. Those are meaningful benefits.

It should not be prescribed solely as a strategy to prevent cardiovascular disease, dementia or aging itself.

Using hormones well means treating the problems they are known to treat while continuing to address the rest of a woman's cardiovascular, metabolic, skeletal and cognitive risk separately.

What About Women Who Do Not Want or Cannot Use Hormones?

Hormone therapy is not the only treatment for menopausal symptoms.

Several nonhormonal prescription therapies can reduce vasomotor symptoms, including selected SSRIs and SNRIs, gabapentin, fezolinetant and other options depending on the individual patient. Behavioral and lifestyle interventions can also improve sleep, metabolic health, body composition and overall well-being even when they do not eliminate vasomotor symptoms completely.

The appropriate treatment depends on which symptoms are present, how disruptive they are, the patient's medical history and what she prefers.

Menopause Is a Useful Time to Reassess the Whole Health Picture

For some women, the most important menopause intervention is hormone therapy. For another woman it may be diagnosing sleep apnea. Another may need treatment for osteoporosis, insulin resistance, hypertension, iron deficiency or depression. Many need more than one thing addressed.

A thoughtful midlife evaluation may include:

• Menopausal symptoms and menstrual history
• Blood pressure and cardiovascular risk
• Lipids, apoB and selected metabolic testing
• Glucose and insulin resistance when clinically relevant
• Bone-health assessment
• Body composition and muscle preservation
• Sleep
• Nutrition and protein intake
• Exercise and resistance training
• Sexual and genitourinary symptoms
• Thyroid, iron or other testing when the history warrants it

This is where longevity medicine can be useful when it remains grounded in medicine. The purpose is not to find an abnormality in every system. It is to identify the risk factors and physiologic changes that can actually be acted upon.

Menopause and Longevity

Menopause itself is not a disease. It does, however, arrive at a time when several determinants of future health begin to become more visible.

Bone density, muscle, visceral fat, blood pressure, lipids, glucose metabolism, sleep and cardiovascular risk can all change during midlife. Some changes are directly influenced by ovarian hormone loss. Others reflect aging, genetics, behavior and preexisting health.

Those differences are clinically useful because they tell us where treatment may help.

The goal is not to medicalize menopause. It is to use the transition as an opportunity to treat symptoms that deserve treatment and identify risks that deserve attention.

Frequently Asked Questions

What age does menopause usually occur?

Natural menopause occurs at different ages, but the average age in the United States is approximately 51 to 52. The menopausal transition commonly begins several years earlier.

Does menopause cause weight gain?

Midlife weight gain is influenced substantially by aging, activity, nutrition, sleep and other metabolic factors. Menopause appears to contribute particularly to changes in body composition and a greater tendency toward abdominal and visceral fat accumulation.

Can menopause cause hair loss?

Hormonal changes may contribute to changes in hair diameter and female-pattern thinning, but hair loss in midlife has many possible causes. Thyroid disease, iron deficiency, rapid weight loss, low protein intake, medications and dermatologic conditions should also be considered.

Is hormone therapy safe?

Risk depends on the individual patient, type and route of hormone therapy, age and time since menopause. For many healthy symptomatic women who begin treatment before age 60 or within about 10 years of menopause and who do not have contraindications, the benefit-risk profile can be favorable. Treatment should still be individualized.

Does hormone therapy prevent heart disease or dementia?

Hormone therapy should not be started solely to prevent cardiovascular disease or dementia. Its strongest established indications are treatment of bothersome menopausal symptoms and prevention of bone loss in appropriately selected women.

Do hormone levels need to be checked to diagnose menopause?

Usually not in women of typical menopausal age with characteristic menstrual changes and symptoms. Hormone concentrations fluctuate substantially during perimenopause, so a single estrogen or FSH measurement may not provide the clarity people expect. Testing is more useful when the presentation is atypical or another diagnosis is being considered.

Selected Clinical References

American College of Obstetricians and Gynecologists. The Menopause Years.

American College of Obstetricians and Gynecologists. Hormone Therapy for Menopause.

National Institute on Aging. What Is Menopause?

The Menopause Society. 2022 Hormone Therapy Position Statement.

The Menopause Society. 2023 Nonhormone Therapy Position Statement.

Educational use only. This article provides general health education and is not a diagnosis or individualized treatment plan. Menopausal symptoms, abnormal bleeding and decisions regarding hormonal or nonhormonal treatment should be evaluated in the context of medical history, medications, age, cardiovascular and thrombotic risk, cancer history and individual preferences.